Safety and immunogenicity of 15-valent pneumococcal conjugate vaccine compared to 13-valent pneumococcal conjugate vaccine in adults ≥65 years of age previously vaccinated with 23-valent pneumococcal polysaccharide vaccine

Background: Pneumococcal disease remains a public health priority in adults. Previous studies have suggested that administration of pneumococcal polysaccharide vaccine or pneumococcal conjugate vaccine within three years following receipt of PPV23 was associated with increased reactogenicity and red...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:Hum Vaccin Immunother
Autori principali: Peterson, James T., Stacey, Helen L., MacNair, John E., Li, Jianing, Hartzel, Jonathan S., Sterling, Tina M., Benner, Patrice, Tamms, Gretchen M., Musey, Luwy K.
Natura: Artigo
Lingua:Inglês
Pubblicazione: Taylor & Francis 2018
Soggetti:
Research Paper
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC6605723/
https://ncbi.nlm.nih.gov/pubmed/30427749
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1080/21645515.2018.1532250
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi